Skip to main content

Advertisement

SpringerLink
Log in

Ga68-DOTA Peptide PET/CT to Detect Occult Mesenchymal Tumor-Inducing Osteomalacia: A Case Series of Three Patients

  • Case Report
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Tumor-induced osteomalacia (TIO) is a rare disease that manifests with paraneoplasic syndrome and overproduction of fibroblast growth factor 23 (FGF23), leading to renal phosphate wasting and hyperphosphaturia, eventually leading to acquired hypophosphatemic osteomalacia. Diagnosis of this disease is often challenging because of the small size of the lesion, which can be localized in bone or soft tissue anywhere in the body. Detecting these occult mesenchymal tumors (OMT) is of great importance as they are potentially curable after tumor resection. The purpose of this case series is to provide some insight into the diagnosis and localization of OMT associated with osteomalacia, particularly using functional imaging with Ga68-DOTA peptide PET/CT scans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;18:R53–77.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1–30.

    Article  PubMed  Google Scholar 

  3. von Falck C, Rodt T, Rosenthal H, Langer F, Goesling T, Knapp WH, et al. (68)Ga-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia. European Journal of Nuclear Medicine and Mol Imaging. 2008;35:1034.

    Article  Google Scholar 

  4. Garcia CA, Spencer RP. Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report. Clin Nucl Med. 2002;27:582–3.

    Article  PubMed  Google Scholar 

  5. Jagtap VS, Sarathi V, Lila AR, Malhotra G, Sankhe SS, Bandgar T, et al. Tumor-induced osteomalacia: a single center experience. Endocr Pract. 2011;17:177–84.

    Article  PubMed  Google Scholar 

  6. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Eng J Med. 2003;348:1656–63.

    Article  CAS  Google Scholar 

  7. Ramon I, Kleynen P, Body JJ, Karmali R. Fibroblast growth factor 23 and its role in phosphate homeostasis. Eur J Endocrinol. 2009;162:1–10.

    Article  PubMed  Google Scholar 

  8. Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab. 2007;92:2374–7.

    Article  CAS  PubMed  Google Scholar 

  9. Hu FK, Yuan F, Jiang CY, Lv DW, Mao BB, Zhang Q, et al. Tumor-induced osteomalacia with elevated fibroblast growth factor 23: A case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature. Chin J Cancer. 2011;30:794–804.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Jadhav S, Kasaliwal R, Lele V, Rangarajan V, Chandra P, Shah H, et al. Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor-based functional scans: a series of nine patients. Clin Endocrinol (Oxf). 2014;81:31–7.

    Article  CAS  Google Scholar 

  11. Uramoto N, Furukawa M, Yoshizaki T. Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx. 2009;36:104–5.

    Article  PubMed  Google Scholar 

  12. Hesse E, Moessinger E, Rosenthal H, Laenger F, Brabant G, Petrich T, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res. 2007;22:158–62.

    Article  CAS  PubMed  Google Scholar 

  13. Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724.

    Article  PubMed  Google Scholar 

  14. Cheung FM, Ma L, Wu WC, Siu TH, Choi PT, Tai YP. Oncogenic osteomalacia associated with an occult phosphaturic mesenchymal tumour: clinico-radiologico-pathological correlation and ultrastructural studies. Hong Kong Med J. 2006;12:319–21.

    CAS  PubMed  Google Scholar 

  15. Duet M, Kerkeni S, Sfar R, Bazille C, Liote F, Orcel P. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med. 2008;33:752–6.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The author gratefully acknowledges the guidance of Dr. Kelvin S.H. Loke and Associate Prof. David Ng in the preparation of this manuscript and also the learning opportunity provided by the Department of Nuclear Medicine at Singapore General Hospital.

Conflict of Interest

Chi Long Ho, the author of this manuscript, declares that he has no conflict of interest.

Informed Consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000.

Author information

Authors and Affiliations

  1. Department of Diagnostic Radiology, Singapore General Hospital, 4 Outram Road, Singapore, 169608, Singapore

    Chi Long Ho

Authors
  1. Chi Long Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chi Long Ho.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ho, C.L. Ga68-DOTA Peptide PET/CT to Detect Occult Mesenchymal Tumor-Inducing Osteomalacia: A Case Series of Three Patients. Nucl Med Mol Imaging 49, 231–236 (2015). https://doi.org/10.1007/s13139-015-0328-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-015-0328-2

Keywords

Search

Navigation